Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Based on metabolism and clearance, a pharmacokinetic interaction is unlikely. However, use of tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product (such as amphotericin B). If concomitant use of emtricitabine/tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be closely monitored.
Use of emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product like amphotericin B.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking